These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1975737)

  • 41. Does sulphasalazine cause folate deficiency in rheumatoid arthritis?
    Grindulis KA; McConkey B
    Scand J Rheumatol; 1985; 14(3):265-70. PubMed ID: 2864741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sulphasalazine: mechanism of action in rheumatoid arthritis.
    Smedegård G; Björk J
    Br J Rheumatol; 1995 Nov; 34 Suppl 2():7-15. PubMed ID: 8535652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
    Järnerot G; Into-Malmberg MB; Esbjörner E
    Scand J Gastroenterol; 1981; 16(5):693-7. PubMed ID: 6119765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo.
    Sheldon P; Pell P
    Adv Exp Med Biol; 1995; 371B():905-8. PubMed ID: 7502923
    [No Abstract]   [Full Text] [Related]  

  • 46. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
    Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
    Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sulphasalazine in arthritis--an old drug rediscovered.
    Taggart AJ
    Clin Rheumatol; 1987 Sep; 6(3):378-83. PubMed ID: 2894913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs.
    Papasouliotis K; Gruffydd-Jones TJ; Sparkes AH; Cripps PJ
    Res Vet Sci; 1995 May; 58(3):263-7. PubMed ID: 7659853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
    Taggart AJ; McDermott BJ; Roberts SD
    Clin Pharmacokinet; 1992 Oct; 23(4):311-20. PubMed ID: 1356683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study.
    Gu GZ; Xia HM; Pang ZQ; Liu ZY; Jiang XG; Chen J
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Feb; 879(5-6):449-56. PubMed ID: 21251889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Azo reduction of sulphasalazine in healthy volunteers.
    Houston JB; Day J; Walker J
    Br J Clin Pharmacol; 1982 Sep; 14(3):395-8. PubMed ID: 6127096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sulphasalazine and male infertility: reversibility and possible mechanism.
    Toovey S; Hudson E; Hendry WF; Levi AJ
    Gut; 1981 Jun; 22(6):445-51. PubMed ID: 6114897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.
    van Hees PA; Bakker JH; van Tongeren JH
    Gut; 1980 Jul; 21(7):632-5. PubMed ID: 6107263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of prostaglandin biosynthesis by sulphasalazine and its metabolites.
    Collier HO; Francis AA; McDonald-Gibson WJ; Saeed SA
    Prostaglandins; 1976 Feb; 11(2):219-25. PubMed ID: 4854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine.
    el-Omar E; Penman I; Cruikshank G; Dover S; Banerjee S; Williams C; McColl KE
    Gut; 1994 Oct; 35(10):1385-8. PubMed ID: 7959192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
    Taffet SL; Das KM
    Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of prostaglandin synthetase in human rectal mucosa.
    Hawkey CJ; Lo Casto M
    Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.
    Pirmohamed M; Coleman MD; Hussain F; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1991 Sep; 32(3):303-10. PubMed ID: 1685664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
    Allgayer H; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.